AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04525092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hemodialysis
Description: Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
Study NCT04525092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Post-dilution Hemodiafiltration
Description: The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
Study NCT05436249 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: At-home therapy
Description: Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends.
Study NCT04730518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga-based group therapy
Description: see above
Study NCT04730518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based group therapy
Description: see above
Study NCT05928806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab 75mg IV
Study NCT05928806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab 450mg IV
Study NCT05928806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg IV
Study NCT05928806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
Study NCT05142709 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1 Immune Checkpoint Inhibitors
Description: used as 1st line treatment for metastatic ESCC.
Study NCT05646056 — intervention group
Intervention type: DEVICE
Intervention: Software
Description: Observation only
Study NCT05180786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Error Fields
Description: Participants will complete a reaching experiment using the robotic arm with error fields turned on.
Study NCT05180786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Error Fields
Description: Participants will complete a reaching experiment using the robotic arm with error fields turned off.
Study NCT06090071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaseMD Laser
Description: The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
Study NCT06090071 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LaseMD Laser
Description: The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
Study NCT06090071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sciton Laser
Description: The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
Study NCT06090071 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sciton Laser
Description: The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
Study NCT06090071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyto A+ Brightening Treatment
Description: Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
Study NCT06090071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phyto A+ Brightening Treatment
Description: Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
Study NCT05177796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05177796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05177796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT05177796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05177796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT05177796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05984745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 Forte® capsules
Description: Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
Study NCT04837014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prescription for regular acetaminophen and naproxen
Description: Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
Study NCT06224049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hNeo-T
Description: After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T. hNeo-T preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning, and the investigators will decide whether to use it. Chemotherapy preconditioning will be performed before hNeo-T transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is \<0.8×10\^9/L and the subject meets the criteria for cell transfusion, the chemotherapy preconditioning will not be performed and subsequent cell transfusion can be performed directly.
Study NCT06224049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion.
Study NCT06224049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion
Study NCT04837014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prescription for regular acetaminophen , naproxen and dilaudid
Description: prescription for regular acetaminophen , naproxen and dilaudid
Study NCT05319470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraocular pressure (IOP)
Description: Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
Study NCT05319470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Break-up Time (TBUT)
Description: TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
Study NCT05319470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conjuctival Hyperemia
Description: Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
Study NCT05319470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Test
Description: Schirmer test will be performed on both eyes to asses tear production.
Study NCT05319470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Fields and OCT RNFL
Description: Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
Study NCT06387316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Oral Stimulation
Description: No oral stimulation
Study NCT06387316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral water stimulation
Description: Oral water stimulation
Study NCT06387316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Salt Stimulation
Description: Oral Salt Stimulation
Study NCT06387316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Sucralose Stimulation
Description: Oral Sucralose Stimulation
Study NCT06387316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Sucrose stimulation
Description: Oral Sucrose stimulation
Study NCT05723770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: instillation of NOV03
Description: This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
Study NCT05163665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure type
Description: Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
Study NCT05163665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure type
Description: Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
Study NCT04844138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program
Description: The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
Study NCT04844138 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program
Description: The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
Study NCT05564117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide tablets orally once daily for 64 weeks.
Study NCT05564117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Semaglutide placebo-matching tablets orally once daily for 64 weeks.
Study NCT04873687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counter Pulsation (ECP) therapy
Description: ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
Study NCT06543992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir
Description: Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
Study NCT03155698 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: microneedling and Platelet rich plasma
Description: Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~* After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days.
Study NCT03155698 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Description: All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
Study NCT06055582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bread
Description: 81g (3 slices) harvest gold white bread as standard food.
Study NCT06055582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mango
Description: 250g of mango pulp of each mango variety was given to the subjects.
Study NCT05301634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infraorbital block
Description: the patients will receive bilateral infraorbital block
Study NCT05301634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: topical intranasal bupivacaine
Description: the patients will receive topical intranasal application of bupivacaine
Study NCT05173636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical lateral glide
Description: A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
Study NCT05173636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization technique
Description: Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
Study NCT04854746 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-GI.1.NN
Description: GI.1 oral vaccine tablet
Study NCT04854746 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Tablets matching in number and appearance to active vaccine tablets
Study NCT06508814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower Insufflation Pressure
Description: Participants underwent laparoscopic hysterectomy with an insufflation pressure that is lower than the standard insufflation pressure used in this type of surgery.
Study NCT06508814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insufflation Pressure
Description: Participants underwent laparoscopic hysterectomy with a standard insufflation pressure.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study NCT04688788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study NCT04307394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifePlans
Description: LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
Study NCT04948125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: 200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
Study NCT04948125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg qd
Study NCT06275399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCT examination
Description: OCT examination for precise evaluation of plaque morphology within the coronary stenosis.
Study NCT06275399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling directly from coronary artery (proximal and distal segment) arteries
Study NCT06275399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of vFFR and shear stress parameters
Description: The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
Study NCT05356663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)
Study NCT05356663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hold Relax
Description: Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
Study NCT06151925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria
Description: mechanical method for induction of labor
Study NCT06151925 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laminaria
Description: mechanical method for induction of labor
Study NCT06151925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal prostaglandin
Description: Vaginal prostaglandin for ripening
Study NCT06151925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal prostaglandin
Description: Vaginal prostaglandin for ripening